Background Concurrent treatment with temozolomide and radiotherapy followed by
maintenance temozolomide is the standard of care for patients with newly diagnosed …

Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …

Despite treatment with the current standard-of-care therapies, patients with newly diagnosed
glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated …

Background We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …

Purpose: To determine if the addition of bevacizumab to radiation therapy and
temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly …

Importance Glioblastomas and malignant gliomas are the most common primary malignant
brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new …

1 Background: Chemoradiation (CRT) with temozolomide (TMZ/RT→ TMZ) is the standard of
care for newly diagnosed GBM. This trial determined if the addition of Bev to standard CRT …

Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in
the United States for recurrent GBM in 2009. In order to review the therapeutic effect of …

In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed
glioblastoma and at the first recurrence. Randomized clinical trials at the second or further …

Purpose This open-label, prospective, multicenter single-arm phase II study combined
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of …